IP Library › Granted Patent US 11,027,014
Granted Patent B2
US 11,027,014 · App. 16/260,914 · Granted Jun 8, 2021

Methods using GDF-15 antibodies for treatment of pulmonary arterial hypertension

Inventors: Lai-Ming Yung (Jamison, PA); Paul B. Yu (Boston, MA)
Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
A61K39/3955A61P11/00A61K38/1841A61K2039/505C07K14/475C07K14/495C07K16/22C07K2317/76C07K2319/30C07K2319/32C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,027,014
App. No.
16/260,914
Granted
Jun 8, 2021
Kind
B2
Abstract

The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGFβ1, TGFβ3, and/or GDF-15.

Claims (3)

1. A method of treating pulmonary arterial hypertension (PAH) in a subject in need of treatment thereof, the method comprising administering a neutralizing antibody against Growth Differentiation Factor 15 (GDF-15) to the subject.

2. The method of claim 1 , wherein the subject has scleroderma or connective tissue disease associated with PAH (APAH-CTD).

3. The method of claim 1 , wherein the subject is determined to have an increased level of GDF-15 relative to a control.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2019
From: YUNG, LAI-MING; YU, PAUL B.
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 048598/0222 →
Continuity (3)
Continuation 15327741
Provisional Application 62031924 · Aug 1, 2014
Related Publication 20190365857A1 · Dec 5, 2019